Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
Friday, Legend Biotech Corporation LEGN and Johnson & Johnson JNJ announced late-breaking three-year follow-up data from the Phase 3 CARTITUDE-4 study.
Dublin, Sept. 30, 2024 (GLOBE NEWSWIRE) -- The "Plaque Psoriasis: Seven-Market Drug Forecast and Market Analysis - Update" report has been added to ResearchAndMarkets.com's offering.
The new full visual range IOL*1 delivers exceptional distance vision2 and 14% smaller readable print size vs PanOptix3 †. 93% of patients become free from glasses at all distances.
15 Best Dividend Stocks for Lifelong Passive Income
06:15am, Monday, 30'th Sep 2024
Dividend sustainability trumps high yields when selecting stocks for passive income. The featured companies span diverse sectors including healthcare, consumer goods, retail, finance, and real estate.
2 Excellent Dividend Stocks to Buy With Less Than $200
05:00am, Saturday, 28'th Sep 2024
Abbott Laboratories' top line was somewhat inconsistent in recent years due to swings in its COVID-related revenues. Johnson & Johnson has been restructuring, spinning off its consumer health segment
AHF Hails HRSA Stance on J&J's Illegal Attack on 340B Program
07:38pm, Friday, 27'th Sep 2024
WASHINGTON--(BUSINESS WIRE)--AHF Hails HRSA Stance on J&J's Illegal Attack on 340B Program.
45 percent reduction in risk of death achieved with CARVYKTI® after three-year follow-up in landmark CARTITUDE-4 study Data featured in a late-breaking oral presentation at the 2024 International M
Minimal residual disease (MRD)-negativity rate of 10-5 more than doubled by 12 months with DARZALEX FASPRO® in maintenance therapy compared to lenalidomide alone, resulting in improvement in 30-month
Study of the first and only subcutaneous quadruplet regimen demonstrates 60.9 percent improvement in minimal residual disease (MRD)-negativity and 43 percent reduction in the risk of progression or de
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
10:05am, Friday, 27'th Sep 2024
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Data from the investigational Phase 1b RedirecTT-1 study demonstrate a safety profile consistent to TALVEY® and TECVAYLI® monotherapies RIO DE JANEIRO , Sept. 27, 2024 /PRNewswire/ -- Johnson & John
Updated data show 100 percent overall response rate with 56 percent of patients achieving complete response or better with weekly dosing, supporting the combinability of the GPRC5D bispecific antibody
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
06:35am, Wednesday, 25'th Sep 2024
A market sell-off this summer resulted in an 8% loss for the S&P 500 over three weeks. These periods can happen at any time during a bull or bear market -- so it's important to prepare for them.
Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note
06:51pm, Tuesday, 24'th Sep 2024
Johnson & Johnson (JNJ) closed at $162.78 in the latest trading session, marking a -0.27% move from the prior day.
J&J Seeks 3rd Talc-Related Bankruptcy: Time to Sell the Stock?
10:16am, Tuesday, 24'th Sep 2024
We suggest a new investor should avoid buying JNJ's stock now due to uncertainty surrounding its legal battles.
